CIS Insulin Market (2024 - 2030) Size, Share & Trends Analysis Report By Product, By Type (Human Insulin, Insulin Analog), By Application (Type 1 Diabetes), By Distribution Channel, By Region, And Segment Forecasts

CIS Insulin Market Size & Trends

The CIS insulin market size was valued at USD 3.05 billion in 2023 and is projected to grow at a CAGR of 5.6% from 2024 to 2030. The rising number of diabetes patients and lifestyle changes causing health issues such as obesity, increased investments in research and development, advancements in insulin products, and the expanding use of CIS insulin for type I and type II diabetes are driving industry growth worldwide.

The CIS insulin market is fueled by several key factors, with the primary driver being the growing prevalence of diabetes across the region. The increasing number of people affected by different types of diabetes has significantly amplified demand for insulin treatment, driving market growth. According to the International Diabetes Federation, the number of adults with diabetes in Europe is projected to rise from 59 million in 2021 to 62 million by 2030.

Technological advancements in insulin production, delivery, safety, and efficacy are also propelling the market. The introduction of novel insulin analogs, biosimilars, and next-generation insulin delivery devices has transformed diabetes management. For instance, Novo Nordisk's ultra-long-acting insulin analog, Tresiba, launched in 2024 in the CIS region, offers improved glycemic control and reduced risk of hypoglycemia for patients.

The growing obese and aging populations in the CIS region are further driving the insulin market. Obesity is a major risk factor for type 2 diabetes, which requires insulin management. The search results indicate that the rising prevalence of obesity, particularly in urban areas, is fueling market growth. Moreover, the rapidly growing elderly population across CIS countries is contributing to the market, as the risk of diabetes increases with age.

Governments in the region have played a crucial role in driving market growth through initiatives focused on patient education, awareness about diabetes management, and increased healthcare expenditure. These factors have been identified as key drivers of the market's growth. Overall, the CIS insulin market is poised for continued growth driven by these factors, as well as the increasing prevalence of diabetes and technological advancements in insulin therapy.

Product Insights

Long-acting Insulin dominated the market and accounted for a share of 52.7% in 2023. Long-acting insulins mimic natural insulin with a slower onset of action and are mainly utilized as basal insulins. Their continuous efforts work to reduce gluconeogenesis in the liver and avoid ketosis in individuals with T1D. Extended-release insulins are commonly administered once a day along with rapid-acting or short-acting insulin for meals. When utilizing an insulin pump for T1D treatment, long-acting insulin is not always necessary.

Biosimilars are expected to register the fastest CAGR of 15.3% over the forecast period. The cost of diabetes care in the CIS continues to rise, with insulin cost growing rapidly. Providers and patients are worried about the accessibility and affordability of these crucial medications that need to be resolved. The presence of biosimilar insulin products could potentially alleviate these problems by bringing more competition into the insulin market, yet they might encounter resistance from both patients and healthcare providers.

Type Insights

Insulin analog led the market with the largest revenue share of 89.0% in 2023. Insulin analogs are a form of engineered insulin that starts working quickly and has an instant impact on the body's functions. The market offers insulin lispro, aspart, and glulisine in this category, all of which have been modified to adjust the amino acid sequence of the B chain in order to decrease the formation of zinc mediated hexamers, a feature present in regular insulin.

The human insulin segment is expected to register substantial growth over the forecast period. Human recombinant insulin remains a popular treatment option for diabetes patients, particularly in resource-constrained settings, due to its cost-effectiveness. Available in various formulations, it offers flexibility in regimen customization.

Application Insights

Type 1 Diabetes dominated the market and accounted for a share of 79.6% in 2023. Type 1 diabetes primarily affects children, teenagers, and some adults. Genetic factors and viruses can trigger this condition, requiring lifelong insulin therapy to regulate blood glucose levels and prevent complications. The high incidence of type 1 diabetes and the need for insulin treatment in the CIS region have fueled demand for CIS insulin products, making it the largest application segment in the market.

Type 2 Diabetes is expected to register the fastest CAGR of 11.6% during the forecast period, driven by the increasing prevalence of the condition in the CIS region. This chronic condition, characterized by insulin resistance and glucose regulation issues, leads to excess sugar in the bloodstream if left untreated. The demand for insulin therapies to manage type 2 diabetes is rising due to a growing sedentary lifestyle, unhealthy diets, and increasing obesity rates.

Distribution Channel Insights

Retail & specialty pharmacies accounted for the largest market revenue share of 89.4% in 2023. The retail pharmacy industry deals with crowded retail sites, continuous shortage of staff, rising prices, and stabilization in generic drug use. In order to be successful in this atmosphere, retail pharmacies of all kinds should aim to gain a deeper understanding of and adjust to evolving consumer choices.

Hospital pharmacies are projected to register significant growth over the forecast period due to their ability to facilitate open communication between healthcare professionals, providing better patient care and access to medical records. This allows for personalized treatment and alternative medication suggestions in case of shortages. As CIS healthcare infrastructure improves, hospital pharmacies' role in insulin distribution is likely to increase, driving market growth.

Regional Insights

CIS Insulin market is expected to witness substantial growth from 2024 to 2030. Key countries analyzed in this study include Poland, Turkey, Ukraine, Uzbekistan, Belarus, and Kazakhstan.Several local authorities offer financial assistance for healthcare services in order to lower the expenses associated with medications. Furthermore, market growth in the region has been driven by government funds allocated for the local development of biosimilar drugs.

Poland CIS Insulin Market Trends

Poland CIS Insulin market held a substantial market share of 10.3% in 2023 due to various factors influencing market growth, including drivers, constraints, opportunities, and threats. This information helps strategy planners in developing policies related to production volume, service delivery, networking, and consumer awareness.

Key CIS Insulin Company Insights

Leading insulin manufacturers are adopting strategies such as new product launches, partnerships, and mergers to increase market share. The arrival of biosimilar insulin has created opportunities for new players. Governments in the CIS region are providing support to local producers, encouraging multinational companies to set up production units. Investments in R&D are also driving innovation in insulin drugs and devices.

Some of the key companies in the CIS Insulin market include

• Novo Nordisk A/S focuses on developing, manufacturing, and selling pharmaceutical products. The company specializes in providing diabetes care, including insulin delivery systems and various other diabetes products. Novo Nordisk is also active in fields such as managing haemostasis, treating growth disorders, and providing hormone replacement therapy.

• Eli Lilly and Company, a pharmaceutical company transforms scientific research into treatments to improve the lives of individuals globally. By utilizing biotechnology, chemistry, and genetic medicine, company is pushing the boundaries of science to address major global health issues.

Recent Developments

• In June 2024, Eli Lilly and Company (NYSE: LLY) revealed intricate findings from SYNERGY-NASH, a phase 2 trial involving 190 participants, with or without type 2 diabetes, investigating the potential use of tirzepatide in adults diagnosed with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis.

• In May 2024, Novo Nordisk released the results of the FRONTIER 2 trial, a 26-week, open-label, randomized, and multicenter study involving 254 participants aged 12 years and above with haemophilia A, with or without inhibitors. The trial compared the effectiveness and safety of weekly and monthly subcutaneous injections of Mim8 to no preventive treatment and previous use of coagulation factor prophylaxis.

CIS Insulin Market Report Scope

CIS Insulin Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the CIS insulin market report based on product, type, application, distribution channel, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Rapid-acting Insulin

  • Long-acting Insulin

  • Combination Insulin

  • Biosimilar

  • Other Products

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Human Insulin

  • Insulin Analog

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Type I Diabetes

  • Type II Diabetes

• Distribution Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals Pharmacies

  • Retail & Specialty Pharmacies

  • Other Distribution Channels

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • Commonwealth of Independent States (CIS)

    • Russia

    • Poland

    • Turkey

    • Ukraine

    • Uzbekistan

    • Belarus

    • Kazakhstan